STOCK TITAN
  1. Home
  2. News
  3. VCYT

Veracyte Inc - VCYT STOCK NEWS

Welcome to our dedicated news page for Veracyte (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Veracyte's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Veracyte's position in the market.

News
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
Rhea-AI Summary
Veracyte, Inc. announces that nine studies showcasing the value of Decipher Prostate and Decipher Bladder testing will be presented at AUA 2024, emphasizing the clinical utility and biological insights of these genomic classifiers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
none
-
News
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
Rhea-AI Summary
Veracyte, Inc. announced that its Decipher Prostate Genomic Classifier has received a 'Level 1B' evidence rating in the 2024 NCCN Clinical Practice Guidelines in Oncology, making it the only gene expression test to achieve this status. The test was recognized for its prognostic value in risk stratifying patients with localized prostate cancer, with recommendations based on extensive clinical evidence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
none
-
News
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
Rhea-AI Summary
Veracyte, Inc. (Nasdaq: VCYT) reported strong financial results for Q4 and full year 2023, with total revenue growing to $98.2 million in Q4 and $361.1 million for the year. The company achieved a 22% increase in total revenue, driven by growth in test volume and revenue from their Afirma and Decipher businesses. Veracyte also highlighted key business achievements, including the acquisition of C2i Genomics Inc. and an agreement with Illumina. Despite a net loss for Q4 2023, the company remains optimistic about future growth and expects positive cash flow for the third consecutive year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.87%
Tags
earnings
News
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
Rhea-AI Summary
Veracyte, Inc. (VCYT) executives to present at Raymond James 45th Annual Institutional Investors Conference. Live webcast scheduled on March 4, 2024, at 9:50 a.m. Eastern Time. Replay available for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
conferences
-
News
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
Rhea-AI Summary
Veracyte, Inc. (Nasdaq: VCYT) will release financial results for Q4 and full-year 2023 on February 22, 2024. A conference call and webcast will follow to discuss the results and provide a business update. The webcast replay will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
earnings
-
News
Veracyte Completes Acquisition of C2i Genomics
Rhea-AI Summary
Veracyte, Inc. (VCYT) has completed the acquisition of C2i Genomics, Inc., adding whole-genome minimal residual disease (MRD) capabilities to its diagnostics platform. The acquisition expands the company's ability to serve patients across the cancer care continuum, allowing them to deliver more value to clinicians and patients, beginning with early cancer diagnosis and risk assessment, and moving further along the patient journey into treatment monitoring and disease recurrence testing. Veracyte plans to develop further MRD tests in several of its focused indications. The transaction details include the acquisition of C2i Genomics for $70 million, paid for with 2.7 million Veracyte shares, with an additional $25 million payable based on the achievement of future performance milestones over the next two years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.79%
Tags
acquisition
News
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
Rhea-AI Summary
Veracyte, Inc. (Nasdaq: VCYT) announces preliminary unaudited financial results for Q4 and full year 2023. Revenue expected to grow by 21%, reaching between $358 million and $359 million. Acquisition of C2i Genomics, Inc. broadens its presence across the cancer care continuum.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.1%
Tags
acquisition earnings
-
News
Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Veracyte, Inc. (Nasdaq: VCYT) will be presenting at the 42nd annual J.P. Morgan Healthcare Conference on January 8, 2024, at 1:30 p.m. Pacific Time. The CEO and CFO will be presenting, and a live webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.51%
Tags
conferences
-
News
Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
Rhea-AI Summary
Veracyte, Inc. (VCYT) announced new data presented at the 24th Annual Meeting of the Society of Urologic Oncology, highlighting clinical observations and translational research on the Decipher Prostate Genomic Classifier. The studies support its clinical utility in the treatment and management of prostate cancer, particularly for active surveillance candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
Rhea-AI Summary
Veracyte, Inc. (Nasdaq: VCYT) has announced that its Percepta Nasal Swab test has been found to accurately determine lung cancer risk among current and former smokers with lung nodules, potentially avoiding unnecessary invasive procedures and accelerating appropriate treatment. The test is simple, non-invasive, and provides insights to objectively assess lung cancer risk, guiding physicians in determining which patients to work up for lung cancer and which to monitor with imaging.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
none
Stock VCYT logo
Veracyte Inc

Nasdaq:VCYT

VCYT Rankings

#2118 Ranked by Market Cap
#2114 Ranked by Stock Gains
N/A Ranked by Dividends

VCYT Stock Data

1.52B
74.51M
1.15%
97.54%
4.85%
Medical Laboratories
Health Care and Social Assistance
Link
US
South San Francisco

About VCYT

veracyte is a pioneering genomic diagnostics company. our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. we ask the right questions to resolve ambiguity and bring assurance to light, rendering tens of thousands of costly and unnecessary surgeries truly unnecessary. we are giving patients a clearer path forward. through scientific rigor we employ the best tools, best science and best minds to create tests that enable a more accurate diagnosis without the need for risky, costly and often unnecessary surgery. veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards. we are making a difference in the lives of physicians and patients. we are doing something real. .